Work

Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma (PTCL) with <10% CD30 expression: Primary analysis results from the phase 2 SGN35-032 study.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.7077

Authors: Swaminathan P. Iyer, Deepa Jagadeesh, Eva Domingo-Domenech, Fabio Benedetti, Antonia Rodriguez Izquierdo, Kamal Bouabdallah, Umberto Vitolo, Tim Illidge, Jingmin Liu, Eeman Shaikh, Steven M. Horwitz

Institutions: The University of Texas MD Anderson Cancer Center, Cleveland Clinic, Case Comprehensive Cancer Center, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, University of Verona, Hospital Universitario 12 De Octubre, Candiolo Cancer Institute, The Christie NHS Foundation Trust, Pfizer (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4410818116

Cites:

Cited by: 1

Related to: 10